These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18615074)

  • 21. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
    Agnarelli A; Chevassut T; Mancini EJ
    Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multiple melanoma-progress in understanding of molecular mechanism and improvement in treatment outcome with introduction of new drugs for multiple myeloma].
    Hanamura I; Iida S
    Gan To Kagaku Ryoho; 2010 May; 37(5):816-21. PubMed ID: 20524255
    [No Abstract]   [Full Text] [Related]  

  • 23. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
    Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
    Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transformation from follicular lymphoma to high-grade B-cell lymphoma/leukemia with additional t(2;8)(p12;q24), with inverse expressions of c-MYC and BCL-2, and light-chain switch.
    Mannouji K; Tasaka T; Akiyama T; Irei I; Sano F; Matsuhashi Y; Wada H; Tohyama K; Sugihara T; Sadahira Y
    Pathol Int; 2009 Apr; 59(4):261-4. PubMed ID: 19351371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene profiling of lymphoma, myeloma, and AML.
    Rogge L; Bianchi E
    MedGenMed; 2003 Jul; 5(3):12. PubMed ID: 14600649
    [No Abstract]   [Full Text] [Related]  

  • 26. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
    Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
    Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.
    Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
    Oncotarget; 2015 Sep; 6(26):22698-705. PubMed ID: 26087190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
    Chng WJ; Huang GF; Chung TH; Ng SB; Gonzalez-Paz N; Troska-Price T; Mulligan G; Chesi M; Bergsagel PL; Fonseca R
    Leukemia; 2011 Jun; 25(6):1026-35. PubMed ID: 21468039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetics. Cancer gene data casts doubt on popular research method.
    Marshall E
    Science; 2012 Nov; 338(6107):593. PubMed ID: 23118161
    [No Abstract]   [Full Text] [Related]  

  • 30. Regulation by c-Myc of ncRNA expression.
    Kenneth NS; White RJ
    Curr Opin Genet Dev; 2009 Feb; 19(1):38-43. PubMed ID: 19179065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leaving home early: reexamination of the canonical models of tumor progression.
    Weinberg RA
    Cancer Cell; 2008 Oct; 14(4):283-4. PubMed ID: 18835030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling multiple myeloma by AID-dependent conditional activation of MYC.
    Kuehl WM
    Cancer Cell; 2008 Feb; 13(2):85-7. PubMed ID: 18242508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expression of PRDI-BF1 beta isoform in multiple myeloma plasma cells.
    Ocaña E; González-García I; Gutiérrez NC; Mora-López F; Brieva JA; Campos-Caro A
    Haematologica; 2006 Nov; 91(11):1579-80. PubMed ID: 17043021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC addiction: a potential therapeutic target in MM.
    Kuehl WM; Bergsagel PL
    Blood; 2012 Sep; 120(12):2351-2. PubMed ID: 22996653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc.
    Dadiani M; Seger D; Kreizman T; Badikhi D; Margalit R; Eilam R; Degani H
    Endocr Relat Cancer; 2009 Sep; 16(3):819-34. PubMed ID: 19398483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNAs in the pathobiology of multiple myeloma.
    Lionetti M; Agnelli L; Lombardi L; Tassone P; Neri A
    Curr Cancer Drug Targets; 2012 Sep; 12(7):823-37. PubMed ID: 22671930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC.
    Benatti S; Atene CG; Fiorcari S; Mesini N; Martinelli S; Zucchini P; Bacchelli F; Maccaferri M; Debbia G; Potenza L; Rossi D; Vallisa D; Trentin L; Gaidano G; Luppi M; Marasca R; Maffei R
    Hematol Oncol; 2021 Dec; 39(5):707-711. PubMed ID: 34431535
    [No Abstract]   [Full Text] [Related]  

  • 38. Further insights into multiple myeloma genetics.
    Drach J
    Haematologica; 2006 Feb; 91(2):147a. PubMed ID: 16461292
    [No Abstract]   [Full Text] [Related]  

  • 39. Pinpointing a Factor in Myeloma Bone Disease.
    Cancer Discov; 2016 Nov; 6(11):1201-1202. PubMed ID: 27658717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.
    Lionetti M; Agnelli L; Mosca L; Fabris S; Andronache A; Todoerti K; Ronchetti D; Deliliers GL; Neri A
    Genes Chromosomes Cancer; 2009 Jun; 48(6):521-31. PubMed ID: 19306352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.